Chromadex Corp (OTCMKTS:CDXC) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday.

A number of other equities research analysts also recently commented on CDXC. Zacks Investment Research downgraded Chromadex Corp from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 15th. HC Wainwright set a $5.00 price objective on Chromadex Corp and gave the company a “buy” rating in a research report on Friday, August 11th.

Chromadex Corp (OTCMKTS CDXC) opened at 4.04 on Friday. The stock has a 50 day moving average price of $3.33 and a 200-day moving average price of $3.16. The firm’s market capitalization is $186.22 million. Chromadex Corp has a 12-month low of $2.25 and a 12-month high of $4.19.

Chromadex Corp (OTCMKTS:CDXC) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by $0.09. Chromadex Corp had a negative net margin of 52.09% and a negative return on equity of 63.19%. The company had revenue of $5.31 million for the quarter, compared to analyst estimates of $11 million. On average, equities research analysts forecast that Chromadex Corp will post ($0.14) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Chromadex Corp (CDXC) Stock Rating Upgraded by ValuEngine” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/10/chromadex-corp-cdxc-stock-rating-upgraded-by-valuengine.html.

In other Chromadex Corp news, insider Robert N. Fried bought 10,000 shares of Chromadex Corp stock in a transaction dated Tuesday, August 15th. The stock was bought at an average price of $3.15 per share, for a total transaction of $31,500.00. Following the completion of the acquisition, the insider now directly owns 583,241 shares of the company’s stock, valued at $1,837,209.15. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Step Holdings Ltd Pioneer bought 786,167 shares of Chromadex Corp stock in a transaction dated Friday, August 18th. The stock was acquired at an average price of $2.60 per share, with a total value of $2,044,034.20. The disclosure for this purchase can be found here. Insiders have bought a total of 798,167 shares of company stock valued at $2,082,154 in the last quarter.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CDXC. Segall Bryant & Hamill LLC lifted its holdings in shares of Chromadex Corp by 0.3% in the first quarter. Segall Bryant & Hamill LLC now owns 38,834 shares of the company’s stock valued at $104,000 after purchasing an additional 133 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of Chromadex Corp in the second quarter valued at $168,000. LMR Partners LLP purchased a new stake in shares of Chromadex Corp in the second quarter valued at $347,000. Goldman Sachs Group Inc. lifted its holdings in shares of Chromadex Corp by 870.6% in the second quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock valued at $698,000 after purchasing an additional 163,817 shares in the last quarter. Finally, North Star Investment Management Corp. lifted its holdings in shares of Chromadex Corp by 78.9% in the second quarter. North Star Investment Management Corp. now owns 265,334 shares of the company’s stock valued at $1,014,000 after purchasing an additional 117,000 shares in the last quarter.

About Chromadex Corp

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Receive News & Stock Ratings for Chromadex Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex Corp and related stocks with our FREE daily email newsletter.